BONESUPPORT HOLDING AB initiates buy-back of ordinary shares for long-term incentive program

About this update from Bonesupport Holding Ab

The Board of Directors of BONESUPPORT HOLDING AB (“BONESUPPORT”) has today resolved to utilize one of the two authorizations to acquire own ordinary shares granted by the Annual General Meeting on 12 May 2026 . The Board of Directors has resolved to acquire a maximum of 373,320 ordinary shares for a total amount of maximum SEK 100 million for the purpose of ensuring BONESUPPORT’s obligations arising from the long-term share savings program LTI 2026 as resolved by the Annual General Meeting on 12 May 2026 . The acquisition of shares will be carried out in accordance with the Market Abuse Regulation (EU) 596/2014 (" MAR ") and the European Commission 's Delegated Regulation (EU) 2016/1052 (the " Safe Harbour Regulation "). The acquisition of shares will be managed by DNB Carnegie Investment Bank AB that will make its own trading decisions regarding the timing of the acquisitions independently of BONESUPPORT. The following terms and conditions apply to the acquisitions of shares: Acquisition of shares shall be made on Nasdaq Stockholm in accordance with Nasdaq Stockholm’s Main Market Rulebook for Issuers of Shares, MAR and the Safe Harbour Regulation. Acquisitions of shares may be made on one or several occasions and shall commence no earlier than 9 June 2026 and shall end no later than 9 July 2026 . A maximum of 373,320 shares may be acquired for a total amount of up to SEK 100 million for the purpose of ensuring BONESUPPORT’s obligations arising from LTI 2026.  Acquisitions shall be made in compliance with the volume and price restrictions set out in Nasdaq Stockholm’s Main Market Rulebook for Issuers of Shares and in the Safe Harbour Regulation, and shall not be made at a price lower than the lowest price at which an independent purchase may take place. Payment for acquired shares shall be made in cash. As per 8 June 2026 , the total number of shares in BONESUPPORT HOLDING AB is 66,764,350, of which 65,859,195 are ordinary shares and 905,155 are Series C shares. BONESUPPORT HOLDING AB holds no ordinary shares and 905,155 Series C shares as per the same date. For more information contact: BONESUPPORT Holding AB Torbjörn Sköld, CEO +46 (0) 46 286 53 70 Håkan Johansson, CFO +46 (0) 46 286 53 70 [email protected] Cord Communications Charlotte Stjerngren +46 (0) 708 76 87 87 [email protected] www.cordcom.se About BONESUPPORT™ BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to 1,175 msek in 2025. Please visit www.bonesupport.com for more information. BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB. Attachments BONESUPPORT HOLDING AB initiates buy-back of ordinary shares for long-term incentive program © Modular Finance, source Nordic Press Releases

View stock analysis, news, and events for Bonesupport Holding Ab